Myeloproliferative Disorders Drugs Global Market Report 2025

Description

Myeloproliferative disorder drugs encompass medications used to address blood cancers arising from stem cell alterations within the bone marrow, the critical site for blood cell production. These drugs target various types of blood malignancies, including myelodysplastic/myeloproliferative disorders.

The primary categories of myeloproliferative disorder drugs include primary myelofibrosis, polycythemia vera (PV), essential thrombocythemia (ET), chronic eosinophilic leukemia or hyper eosinophilic syndrome (HES), and systemic mastocytosis (SM). Primary myelofibrosis refers to an uncommon chronic blood condition characterized by abnormal synthesis of fibrous tissue in the bone marrow, leading to reduced blood cell production and the formation of scar tissue. These drugs belong to categories such as JAK2 inhibitors, anti-neoplastic agents, demethylation agents, imatinib mesylate, and others. They can be administered orally, parenterally, or through other means. Distribution channels include hospital pharmacies, retail outlets, and drug stores.

The myeloproliferative disorders drugs market research report is one of a series of new reports from The Business Research Company that provides myeloproliferative disorders drugs market statistics, including myeloproliferative disorders drugs industry global market size, regional shares, competitors with a myeloproliferative disorders drugs market share, detailed myeloproliferative disorders drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myeloproliferative disorders drugs industry. This myeloproliferative disorders drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myeloproliferative disorders drugs market size has grown steadily in recent years. It will grow from$9.47 billion in 2024 to $9.92 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increased incidence of myeloproliferative disorders, advancements in understanding disease mechanisms, clinical research and drug development, improvements in diagnosis and screening, patient advocacy and awareness

The myeloproliferative disorders drugs market size is expected to see steady growth in the next few years. It will grow to $11.73 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to aging population, advancements in precision medicine, emergence of novel therapies, global focus on rare diseases, government initiatives and healthcare policies. Major trends in the forecast period include precision medicine approaches, clinical trials for investigational therapies, improved symptom management, expanded use of ruxolitinib, focus on disease biomarkers.

The anticipated increase in myeloproliferative disorders is poised to drive the growth of the market for drugs addressing these conditions. Myeloproliferative disorders, distinct from acute leukemia, entail abnormal cellular growth in one or more blood cell lines. This rise is chiefly attributed to genetic factors, environmental exposures such as radiation or chemicals, and the aging population. Medications for myeloproliferative diseases act by blocking the BCR-ABL protein, hindering downstream phosphorylation processes, thereby aiding in their treatment. Notably, according to the National Institute of Health in August 2022, chronic myelogenous leukemia was more prevalent in men, with an incidence rate of approximately 2.4 new cases per 100,000 compared to 1.4 new cases per 100,000 in women, signifying the driving force behind the market's growth.

The trajectory of the myeloproliferative disorders drug market is expected to be significantly influenced by increased investments in research and development. Such investments refer to the financial commitments made by companies to drive the discovery and application of new knowledge for product development, anticipating commercial gain. These investments are channeled towards innovating novel treatments, evident in the robust pipeline of drugs for myeloproliferative disorders. Notably, as per the National Center for Science and Engineering Statistics in September 2023, federal commitments for research and experimental development surged by 13.6% ($22.7 billion) from FY 2020 to FY 2021, reaching an all-time high of $190.2 billion, fostering growth in the myeloproliferative disorders drug market.

Product innovation stands as a prominent trend shaping the landscape of myeloproliferative disorder drugs. Key industry players are dedicated to crafting novel products to fortify their market standing. For instance, in September 2023, GSK plc announced FDA approval for momelotinib to treat primary myelofibrosis, a myeloproliferative disorder. This medication, momelotinib, operates uniquely by blocking three crucial signaling pathways activin A receptor type I (ACVR1), Janus kinase (JAK) 1, and JAK2. Its inhibition of JAK1 and JAK2 can potentially alleviate splenomegaly and other symptoms associated with the disorder, while also reducing hepcidin levels, known to contribute to anemia in myelofibrosis.

Major players in the myeloproliferative disorder drugs market are strategically focusing on introducing and obtaining approvals for advanced drug solutions, aiming to gain a competitive edge. The introduction and approval of these innovative drug solutions significantly enhance the availability of advanced therapies for patients grappling with myeloproliferative disorders. Notably, in September 2023, Novartis AG disclosed the National Institute for Health and Care Excellence's (NICE) approval for Jakavi (ruxolitinib), a JAK 1/2 inhibitor sanctioned for treating polycythaemia vera (PV). This approval grants access to Ruxolitinib for eligible patients in England and Wales, addressing an unmet treatment need as a substantial percentage of patients under existing therapies develop resistance or intolerance. PV, a subtype of myeloproliferative disorder, poses serious health risks and leads to approximately 1,130 new diagnoses per year in the UK.

In May 2022, Merk, a renowned biopharmaceutical firm based in the US, completed the acquisition of Imago BioSciences Inc. for $1.35 billion. This strategic acquisition is anticipated to bolster Merk's standing as a key player in clinical development, leveraging Imago BioSciences' expertise. Particularly, it aims to optimize the therapeutic potential of bomedemstat, an LSD1 inhibitor, and Imago's pipeline. Additionally, this move reinforces Merk's foothold in the expanding field of hematology. Imago BioSciences, a US-based clinical-stage biopharmaceutical company, specializes in the discovery and development of groundbreaking medications aimed at treating myeloproliferative neoplasms.

Major companies operating in the myeloproliferative disorders drugs market include Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Incyte Corporation, Eli Lilly and Co, F Hoffmann-La Roche Ltd., Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals plc, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International Gmbh, Sanofi Aventis Inc., AstraZeneca AB, Apotex Inc, Celgene Co., Gamida Cell Ltd., Geron Co., Promedior Inc., Johnson & Johnson Private Limited, AbbVie Inc., AOP Orphan Pharmaceuticals AG, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Chemical Pharma Co. Ltd., Eisai Pharmaceuticals India Pvt. Ltd.

North America was the largest region in the myeloproliferative disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the myeloproliferative disorders drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The myeloproliferative disorder drugs market consists of sales of jasatinib, nilotinib, jakafi, hydroxyurea, and gleevec. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myeloproliferative Disorders Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myeloproliferative disorders drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myeloproliferative disorders drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myeloproliferative disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Primary Myelofibrosis; Polycythemia Vera (PV); Essential Thrombocythemia (ET); Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES); Systemic Masto cytosis (SM)
2) By Drug Type: JAK2 Inhibitors; Anti-Neoplastics; Demethylation Agents; Imatinib Mesylate; Other Drug Types
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Stores; Drug Stores
Subsegments:
1) By Primary Myelofibrosis: JAK Inhibitors; Immunomodulatory Agents; Supportive Care
2) By Polycythemia Vera (PV): JAK Inhibitors; Hydroxyurea; Phlebotomy; Interferon-alpha
3) By Essential Thrombocythemia (ET): JAK Inhibitors; Hydroxyurea; Anagrelide; Interferon-alpha
4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors; Corticosteroids; Interferon-alpha
5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors; Corticosteroids; Antihistamines; Immunotherapy
Companies Mentioned: Novartis AG; Bristol-Myers Squibb Company; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24356

1. Executive Summary

2. Myeloproliferative Disorders Drugs Market Characteristics

3. Myeloproliferative Disorders Drugs Market Trends And Strategies

4. Myeloproliferative Disorders Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Myeloproliferative Disorders Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Myeloproliferative Disorders Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Myeloproliferative Disorders Drugs Market Growth Rate Analysis
5.4. Global Myeloproliferative Disorders Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Myeloproliferative Disorders Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Myeloproliferative Disorders Drugs Total Addressable Market (TAM)

6. Myeloproliferative Disorders Drugs Market Segmentation

6.1. Global Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Myelofibrosis
Polycythemia Vera (PV)
Essential Thrombocythemia (ET)
Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES)
Systemic Masto cytosis (SM)
6.2. Global Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
JAK2 Inhibitors
Anti-Neoplastics
Demethylation Agents
Imatinib Mesylate
Other Drug Types
6.3. Global Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Myeloproliferative Disorders Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Stores
Drug Stores
6.5. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Primary Myelofibrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
JAK Inhibitors
Immunomodulatory Agents
Supportive Care
6.6. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Polycythemia Vera (PV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
JAK Inhibitors
Hydroxyurea
Phlebotomy
Interferon-alpha
6.7. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Essential Thrombocythemia (ET), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
JAK Inhibitors
Hydroxyurea
Anagrelide
Interferon-alpha
6.8. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors
Corticosteroids
Interferon-alpha
6.9. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Systemic Mastocytosis (SM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors
Corticosteroids
Antihistamines
Immunotherapy

7. Myeloproliferative Disorders Drugs Market Regional And Country Analysis

7.1. Global Myeloproliferative Disorders Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Myeloproliferative Disorders Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myeloproliferative Disorders Drugs Market

8.1. Asia-Pacific Myeloproliferative Disorders Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myeloproliferative Disorders Drugs Market

9.1. China Myeloproliferative Disorders Drugs Market Overview
9.2. China Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myeloproliferative Disorders Drugs Market

10.1. India Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myeloproliferative Disorders Drugs Market

11.1. Japan Myeloproliferative Disorders Drugs Market Overview
11.2. Japan Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myeloproliferative Disorders Drugs Market

12.1. Australia Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myeloproliferative Disorders Drugs Market

13.1. Indonesia Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myeloproliferative Disorders Drugs Market

14.1. South Korea Myeloproliferative Disorders Drugs Market Overview
14.2. South Korea Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myeloproliferative Disorders Drugs Market

15.1. Western Europe Myeloproliferative Disorders Drugs Market Overview
15.2. Western Europe Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myeloproliferative Disorders Drugs Market

16.1. UK Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myeloproliferative Disorders Drugs Market

17.1. Germany Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myeloproliferative Disorders Drugs Market

18.1. France Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myeloproliferative Disorders Drugs Market

19.1. Italy Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myeloproliferative Disorders Drugs Market

20.1. Spain Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myeloproliferative Disorders Drugs Market

21.1. Eastern Europe Myeloproliferative Disorders Drugs Market Overview
21.2. Eastern Europe Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myeloproliferative Disorders Drugs Market

22.1. Russia Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myeloproliferative Disorders Drugs Market

23.1. North America Myeloproliferative Disorders Drugs Market Overview
23.2. North America Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myeloproliferative Disorders Drugs Market

24.1. USA Myeloproliferative Disorders Drugs Market Overview
24.2. USA Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myeloproliferative Disorders Drugs Market

25.1. Canada Myeloproliferative Disorders Drugs Market Overview
25.2. Canada Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myeloproliferative Disorders Drugs Market

26.1. South America Myeloproliferative Disorders Drugs Market Overview
26.2. South America Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myeloproliferative Disorders Drugs Market

27.1. Brazil Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myeloproliferative Disorders Drugs Market

28.1. Middle East Myeloproliferative Disorders Drugs Market Overview
28.2. Middle East Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myeloproliferative Disorders Drugs Market

29.1. Africa Myeloproliferative Disorders Drugs Market Overview
29.2. Africa Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myeloproliferative Disorders Drugs Market Competitive Landscape And Company Profiles

30.1. Myeloproliferative Disorders Drugs Market Competitive Landscape
30.2. Myeloproliferative Disorders Drugs Market Company Profiles
- 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Myeloproliferative Disorders Drugs Market Other Major And Innovative Companies

31.1. Incyte Corporation
31.2. Eli Lilly and Co
31.3. F Hoffmann-La Roche Ltd.
31.4. Mylan NV
31.5. Fresenius Kabi AG
31.6. Hikma Pharmaceuticals plc
31.7. GSK plc
31.8. Bayer AG
31.9. Sun Pharmaceutical Industries Ltd.
31.10. Boehringer Ingelheim International Gmbh
31.11. Sanofi Aventis Inc.
31.12. AstraZeneca AB
31.13. Apotex Inc
31.14. Celgene Co.
31.15. Gamida Cell Ltd.

32. Global Myeloproliferative Disorders Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myeloproliferative Disorders Drugs Market

34. Recent Developments In The Myeloproliferative Disorders Drugs Market

35. Myeloproliferative Disorders Drugs Market High Potential Countries, Segments and Strategies

35.1 Myeloproliferative Disorders Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Myeloproliferative Disorders Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Myeloproliferative Disorders Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer